Healthcare provider profile · identity verified

David Mach, D.O.

Family Practice · ROSEVILLE, CA · NPI 1821070202

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	375	128
Levothyroxine Sodium	Levothyroxine Sodium	260	85
Lisinopril	Lisinopril	229	77
Amlodipine Besylate	Amlodipine Besylate	188	67
Losartan Potassium	Losartan Potassium	150	54
Gabapentin	Gabapentin	149	50
Sertraline Hcl	Sertraline Hcl	147	34
Omeprazole	Omeprazole	144	48
Metformin Hcl Er	Metformin Hcl	125	35
Atenolol	Atenolol	117	36
Metoprolol Succinate	Metoprolol Succinate	111	37
Simvastatin	Simvastatin	109	42
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	106	34
Fluticasone Propionate	Fluticasone Propionate	103	44
Pantoprazole Sodium	Pantoprazole Sodium	103	37
Albuterol Sulfate Hfa	Albuterol Sulfate	97	46
Tamsulosin Hcl	Tamsulosin Hcl	83	34
Famotidine	Famotidine	77	25
Metformin Hcl	Metformin Hcl	74	29
Rosuvastatin Calcium	Rosuvastatin Calcium	74	28
Montelukast Sodium	Montelukast Sodium	71	23
Trazodone Hcl	Trazodone Hcl	68	21
Duloxetine Hcl	Duloxetine Hcl	61	24
Meloxicam	Meloxicam	59	34
Alendronate Sodium	Alendronate Sodium	56	14
Pravastatin Sodium	Pravastatin Sodium	56	19
Venlafaxine Hcl Er	Venlafaxine Hcl	53	13
Allopurinol	Allopurinol	51	15
Metoprolol Tartrate	Metoprolol Tartrate	50	14
Hydroxyzine Hcl	Hydroxyzine Hcl	49	17
Jardiance	Empagliflozin	48	12
Zolpidem Tartrate	Zolpidem Tartrate	47	12
Clopidogrel	Clopidogrel Bisulfate	45	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	11
Eliquis	Apixaban	43	14
Ozempic	Semaglutide	42	suppressed
Finasteride	Finasteride	41	11
Fenofibrate	Fenofibrate Nanocrystallized	38	suppressed
Furosemide	Furosemide	37	14
Potassium Chloride	Potassium Chloride	37	12
Benazepril Hcl	Benazepril Hcl	36	suppressed
Azelastine Hcl	Azelastine Hcl	35	15
Tramadol Hcl	Tramadol Hcl	35	16
Donepezil Hcl	Donepezil Hcl	34	suppressed
Bupropion Xl	Bupropion Hcl	33	11
Hydralazine Hcl	Hydralazine Hcl	31	suppressed
Synthroid	Levothyroxine Sodium	31	suppressed
Alprazolam	Alprazolam	30	12
Diclofenac Sodium	Diclofenac Sodium	30	15
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Lorazepam	Lorazepam	29	suppressed
Rybelsus	Semaglutide	29	suppressed
Baclofen	Baclofen	28	suppressed
Bupropion Hcl Sr	Bupropion Hcl	28	suppressed
Valsartan	Valsartan	28	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	26	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	26	suppressed
Dutasteride	Dutasteride	24	suppressed
Hydrocortisone	Hydrocortisone	24	14
Nystatin	Nystatin	23	suppressed
Oxycontin	Oxycodone Hcl	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	17
Hydrochlorothiazide	Hydrochlorothiazide	22	suppressed
Cephalexin	Cephalexin	21	18
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Clonazepam	Clonazepam	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Morphine Sulfate Er	Morphine Sulfate	20	suppressed
Acyclovir	Acyclovir	19	suppressed
Glipizide Er	Glipizide	19	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Prednisone	Prednisone	19	18
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	14
Temazepam	Temazepam	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Colesevelam Hcl	Colesevelam Hcl	16	suppressed
Lidocaine	Lidocaine	16	suppressed
Mounjaro	Tirzepatide	16	suppressed
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Buprenorphine	Buprenorphine	15	suppressed
Carvedilol	Carvedilol	15	suppressed
Diazepam	Diazepam	15	suppressed
Febuxostat	Febuxostat	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	12
Terazosin Hcl	Terazosin Hcl	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Estradiol	Estradiol	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Ibandronate Sodium	Ibandronate Sodium	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	11	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Azithromycin	Azithromycin	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Loperamide	Loperamide Hcl	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error